Deadline
Passed
Lead Plaintiff Deadline: November 20, 2020
Please Upload related files below
Fill in below.
Looking for more?
05
Nov 2019
14
Jul 2020
Throughout the class period defendants’ statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.
In order to be included in the lawsuit, you must have incurred a loss on shares of Nextcure, either: A) purchased or acquired during the class period listed above, if applicable; or B) pursuant to the Initial Public Offering (IPO) of Nextcure, if applicable.
If you suffered a loss in Nextcure during the relevant time frame, or pursuant to Nextcure’s IPO if listed above, you have until November 20, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.